サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1790481

米国の抗生物質耐性市場規模、シェア、動向分析レポート：疾患別、病原体別、薬剤クラス別、作用機序別、流通チャネル別、セグメント別予測、2025年～2030年

U.S. Antibiotic Resistance Market Size, Share, & Trends Analysis Report By Disease (cUTI, CDI), By Pathogen, By Drug Class, By Mechanism of Action, By Distribution Channel, And Segment Forecasts, 2025 - 2030

出版日
ページ情報
英文 80 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.30円
米国の抗生物質耐性市場規模、シェア、動向分析レポート：疾患別、病原体別、薬剤クラス別、作用機序別、流通チャネル別、セグメント別予測、2025年～2030年
出版日: 2025年07月10日
発行: Grand View Research
ページ情報: 英文 80 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

米国の抗生物質耐性市場サマリー

米国の抗生物質耐性市場規模は2024年に30億9,000万米ドルと推計され、2030年には39億9,000万米ドルに達し、2025年から2030年までのCAGRは4.4%で成長すると予測されます。抗生物質の誤用や過剰使用の増加により、市場の成長が見込まれています。

CDCによると、米国では毎年280万人以上の抗菌薬耐性感染症が報告され、3万5,000人が死亡しています。さらに、公衆衛生上の懸念の高まりと新しい抗生物質療法の必要性が、市場の成長を促進すると予想されています。WHOによると、動物、ヒト、植物における抗生物質の過剰使用と誤用が、薬剤耐性病原体の開発の主な原因となっています。抗生物質耐性は感染症の治療を困難にし、がん化学療法や帝王切開や人工股関節置換術などの手術を含む医療治療をより危険なものにしています。抗生物質耐性市場は、既存の薬剤に対する耐性菌の増加に対抗できる治療に対する緊急の需要によって、力強い成長を遂げています。

抗生物質耐性菌による感染症に罹患すると、感染症を効果的に治療できる抗生物質が少なくなるため、病気の管理が難しくなります。さらに、これらの耐性菌は他の人に感染する可能性があり、感染が拡大するリスクが高まる。まれに、治療の選択肢がほとんどない場合もあります。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 米国の抗生物質耐性市場の変数、動向、範囲

  • 市場系統の見通し
    • 親市場の見通し
    • 関連/付随市場の見通し
  • 市場力学
    • 市場促進要因分析
    • 市場抑制要因分析

第4章 米国の抗生物質耐性市場分析ツール

  • 業界分析- ポーターのファイブフォース分析
    • サプライヤーの力
    • 買い手の力
    • 代替の脅威
    • 新規参入の脅威
    • 競争企業間の敵対関係
  • PESTEL分析
    • 政治情勢
    • 技術的情勢
    • 経済情勢
  • 米国の抗生物質耐性市場：パイプライン分析

第5章 米国の抗生物質耐性市場：疾患推定・動向分析

  • 疾患セグメントダッシュボード
  • 米国の抗生物質耐性市場：疾患変動分析
  • 米国の抗生物質耐性市場の規模と動向分析（疾患別、2018～2030年）
  • CUTI
  • CDI
  • ABSSSI
  • HABP
  • CABP
  • cIAI
  • BSI

第6章 米国の抗生物質耐性市場：病原体推定・動向分析

  • 病原体セグメントダッシュボード
  • 米国の抗生物質耐性市場：病原体変動分析
  • 米国の抗生物質耐性市場の規模と動向分析（病原体別、2018～2030年）
  • 大腸菌
  • クレブシエラ・ニューモニエ
  • 緑膿菌
  • 黄色ブドウ球菌
  • A. バウマニ
  • 肺炎球菌
  • インフルエンザ菌
  • CDI
  • エンテロコッカス・フェシウム

第7章 米国の抗生物質耐性市場：薬剤クラスの推定・動向分析

  • 薬物クラスセグメントダッシュボード
  • 米国の抗生物質耐性市場：薬剤クラスの変動分析
  • 米国の抗生物質耐性市場規模と動向分析（薬剤クラス別、2018～2030年）
  • オキサゾリジノン
  • リポグリコペプチド
  • テトラサイクリン
  • 併用療法
  • セファロスポリン
  • その他

第8章 米国の抗生物質耐性市場：作用機序の推定・動向分析

  • 作用機序セグメントダッシュボード
  • 米国の抗生物質耐性市場：作用機序の変動分析
  • 米国の抗生物質耐性市場規模と動向分析（作用機序別、2018～2030年）
  • タンパク質合成阻害剤
  • 細胞壁合成阻害剤
  • RNA合成阻害剤
  • DNA合成阻害剤
  • その他

第9章 米国の抗生物質耐性市場：流通チャネルの推定・動向分析

  • 流通チャネルセグメントダッシュボード
  • 米国の抗生物質耐性市場：流通変動分析
  • 米国の抗生物質耐性市場規模と動向分析（流通チャネル別、2018～2030年）
  • 小売薬局
  • 病院薬局
  • オンライン薬局

第10章 競合情勢

  • 主要市場参入企業による最近の動向と影響分析
  • 企業/競合の分類
  • ベンダー情勢
    • Key company heat map analysis, 2024
  • 企業プロファイル
    • Melinta Therapeutics
    • Merck &Co., Inc.
    • Melinta Therapeutics LLC
    • Theravance Biopharma.
    • Paratek Pharmaceuticals, Inc.
    • Seres Therapeutics
    • AbbVie Inc.
図表

List of Tables

  • Table 1 List of Abbreviations
  • Table 2 U.S. Antibiotic Resistance market, by Disease, 2018 - 2030 (USD Million)
  • Table 3 U.S. Antibiotic Resistance market, by Pathogen, 2018 - 2030 (USD Million)
  • Table 4 U.S. Antibiotic Resistance market, by Drug Class, 2018 - 2030 (USD Million)
  • Table 5 U.S. Antibiotic Resistance market, by Mechanism of Action, 2018 - 2030 (USD Million)
  • Table 6 U.S. Antibiotic Resistance market, by Distribution Channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 U.S. antibiotic resistance market: market outlook
  • Fig. 10 U.S. antibiotic resistance competitive insights
  • Fig. 11 Parent market outlook
  • Fig. 12 Related/ancillary market outlook
  • Fig. 13 Penetration and growth prospect mapping
  • Fig. 14 Industry value chain analysis
  • Fig. 15 U.S. antibiotic resistance market driver impact
  • Fig. 16 U.S. antibiotic resistance market restraint impact
  • Fig. 17 U.S. antibiotic resistance market strategic initiatives analysis
  • Fig. 18 U.S. antibiotic resistance market: Disease movement analysis
  • Fig. 19 U.S. antibiotic resistance market: Disease outlook and key takeaways
  • Fig. 20 cUTI market estimates and forecast, 2018 - 2030
  • Fig. 21 CDI estimates and forecast, 2018 - 2030
  • Fig. 22 ABSSSI market estimates and forecast, 2018 - 2030
  • Fig. 23 HABP market estimates and forecast, 2018 - 2030
  • Fig. 24 CABP market estimates and forecast, 2018 - 2030
  • Fig. 25 cIAI estimates and forecast, 2018 - 2030
  • Fig. 26 BSI estimates and forecast, 2018 - 2030
  • Fig. 27 U.S. antibiotic resistance market: Pathogen movement analysis
  • Fig. 28 U.S. antibiotic resistance market: Pathogen outlook and key takeaways
  • Fig. 29 E. coli market estimates and forecasts, 2018 - 2030
  • Fig. 30 klebsiella pneumoniae market estimates and forecasts, 2018 - 2030
  • Fig. 31 P. aeruginosa market estimates and forecasts, 2018 - 2030
  • Fig. 32 S. aureus market estimates and forecasts, 2018 - 2030
  • Fig. 33 A. baumannii market estimates and forecasts, 2018 - 2030
  • Fig. 34 Strep. Pneumoniae market estimates and forecasts, 2018 - 2030
  • Fig. 35 H. influenzae market estimates and forecasts, 2018 - 2030
  • Fig. 36 CDI market estimates and forecasts, 2018 - 2030
  • Fig. 37 Enterococcus fecium market estimates and forecasts, 2018 - 2030
  • Fig. 38 U.S. antibiotic resistance market: Drug class movement analysis
  • Fig. 39 U.S. antibiotic resistance market: Drug class outlook and key takeaways
  • Fig. 40 Oxazolidinones market estimates and forecasts, 2018 - 2030
  • Fig. 41 Lipoglycopeptides market estimates and forecasts, 2018 - 2030
  • Fig. 42 Tetracyclines market estimates and forecasts, 2018 - 2030
  • Fig. 43 Combination therapies market estimates and forecasts, 2018 - 2030
  • Fig. 44 Cephalosporins market estimates and forecasts, 2018 - 2030
  • Fig. 45 Others market estimates and forecasts, 2018 - 2030
  • Fig. 46 U.S. antibiotic resistance market: Mechanism of action movement analysis
  • Fig. 47 U.S. antibiotic resistance market: Mechanism of action outlook and key takeaways
  • Fig. 48 Protein synthesis inhibitors market estimates and forecasts, 2018 - 2030
  • Fig. 49 Cell wall synthesis inhibitors market estimates and forecasts, 2018 - 2030
  • Fig. 50 RNA synthesis inhibitors market estimates and forecasts, 2018 - 2030
  • Fig. 51 DNA synthesis inhibitors market estimates and forecasts, 2018 - 2030
  • Fig. 52 Others market estimates and forecasts, 2018 - 2030
  • Fig. 53 U.S. antibiotic resistance market: Distribution channel movement analysis
  • Fig. 54 U.S. antibiotic resistance market: Distribution channel outlook and key takeaways
  • Fig. 55 Retail pharmacies market estimates and forecasts, 2018 - 2030
  • Fig. 56 Hospital pharmacies market estimates and forecasts, 2018 - 2030
  • Fig. 57 Online pharmacies market estimates and forecasts, 2018 - 2030
目次
Product Code: GVR-4-68040-664-4

U.S. Antibiotic Resistance Market Summary

The U.S. antibiotic esistance market size was estimated at USD 3.09 billion in 2024 and is projected to reach USD 3.99 billion by 2030, growing at a CAGR of 4.4% from 2025 to 2030. The market is expected to grow, driven by the rising misuse and overuse of antibiotics.

According to the CDC, more than 2.8 million antimicrobial-resistant infections are reported every year in the U.S., leading to 35,000 deaths. Moreover, the rise of public health concerns and the need for new antibiotic therapies are expected to drive market growth. According to the WHO, the overuse and misuse of antibiotics in animals, humans, and plants are the main reasons for the development of drug-resistant pathogens. Antibiotic resistance makes infections hard to treat and makes medical treatments, including cancer chemotherapy and surgeries such as cesarean sections and hip replacements, riskier. The market for antibiotic therapies is witnessing strong growth, driven by the urgent demand for treatments that can counteract rising resistance to existing drugs.

When a person contracts an infection caused by antibiotic-resistant bacteria, managing the illness becomes more challenging because fewer antibiotics can effectively treat the infection. In addition, these resistant bacteria can be transmitted to others, increasing the risk of wider spread. There are some rare instances where very few treatment options may be available.

U.S. Antibiotic Resistance Market Report Segmentation

This report forecasts revenue at the country level and analyzes the latest industry trends in each sub-segment from 2018 to 2030. For this study, Grand View Research has segmented the U.S. Antibiotic Resistance Market report based on disease, pathogen, drug class, mechanism of action, and distribution channel:

  • Disease Outlook (Revenue in USD Million, 2018 - 2030)
  • cUTI
  • CDI
  • ABSSSI
  • HABP
  • CABP
  • cIAI
  • BSI
  • Pathogen Outlook (Revenue in USD Million, 2018 - 2030)
  • E. coli
  • klebsiella pneumoniae
  • P. aeruginosa
  • S. aureus
  • baumannii
  • Strep. Pneumoniae
  • H. influenzae
  • CDI
  • Enterococcus fecium
  • Drug Class Outlook (Revenue in USD Million; 2018 - 2030)
  • Oxazolidinones
  • Lipoglycopeptides
  • Tetracyclines
  • Combination therapies
  • Cephalosporins
  • Others
  • Mechanism of Action Outlook (Revenue in USD Million; 2018 - 2030)
  • Protein Synthesis Inhibitors
  • Cell Wall Synthesis Inhibitors
  • RNA Synthesis Inhibitors
  • DNA Synthesis Inhibitors
  • Others
  • Distribution Channel Outlook (Revenue in USD Million; 2018 - 2030)
  • Retail Pharmacies
  • Hospital Pharmacies
  • Online Pharmacies

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Disease
    • 1.2.2. Pathogen
    • 1.2.3. Drug Class
    • 1.2.4. Mechanism of Action
    • 1.2.5. Distribution Channel
    • 1.2.6. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Disease outlook
    • 2.2.2. Pathogen outlook
    • 2.2.3. Drug Class outlook
    • 2.2.4. Mechanism of Action
    • 2.2.5. Distribution Channel
  • 2.3. Competitive Insights

Chapter 3. U.S. Antibiotic Resistance Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
    • 3.2.2. Market restraint analysis

Chapter 4. U.S. Antibiotic Resistance Market Analysis Tools

  • 4.1. Industry Analysis - Porter's
    • 4.1.1. Supplier power
    • 4.1.2. Buyer power
    • 4.1.3. Substitution threat
    • 4.1.4. Threat of new entrant
    • 4.1.5. Competitive rivalry
  • 4.2. PESTEL Analysis
    • 4.2.1. Political landscape
    • 4.2.2. Technological landscape
    • 4.2.3. Economic landscape
  • 4.3. U.S. Antibiotic Resistance Market: Pipeline Analysis

Chapter 5. U.S. Antibiotic Resistance Market: Disease Estimates & Trend Analysis

  • 5.1. Disease Segment Dashboard
  • 5.2. U.S. Antibiotic Resistance Market: Disease Movement Analysis
  • 5.3. U.S. Antibiotic Resistance Market Size & Trend Analysis, by Disease, 2018 to 2030 (USD Million)
  • 5.4. cUTI
    • 5.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5. CDI
    • 5.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6. ABSSSI
    • 5.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.7. HABP
    • 5.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.8. CABP
    • 5.8.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.9. cIAI
    • 5.9.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.10. BSI
    • 5.10.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. U.S. Antibiotic Resistance Market: Pathogen Estimates & Trend Analysis

  • 6.1. Pathogen Segment Dashboard
  • 6.2. U.S. Antibiotic Resistance Market: Pathogen Movement Analysis
  • 6.3. U.S. Antibiotic Resistance Market Size & Trend Analysis, by Pathogen, 2018 to 2030 (USD Million)
  • 6.4. E. coli
    • 6.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5. klebsiella pneumoniae
    • 6.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. P. aeruginosa
    • 6.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7. S. aureus
    • 6.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.8. A. baumannii
    • 6.8.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.9. Strep. Pneumoniae
    • 6.9.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.10. H. influenzae
    • 6.10.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.11. CDI
    • 6.11.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.12. Enterococcus fecium
    • 6.12.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. U.S. Antibiotic Resistance Market: Drug Class Estimates & Trend Analysis

  • 7.1. Drug Class Segment Dashboard
  • 7.2. U.S. Antibiotic Resistance Market: Drug Class Movement Analysis
  • 7.3. U.S. Antibiotic Resistance Market Size & Trend Analysis, by Drug Class, 2018 to 2030 (USD Million)
  • 7.4. Oxazolidinones
    • 7.4.1. Market estimates and forecasts 2018 to 2030 (USD million)
  • 7.5. Lipoglycopeptides
    • 7.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Tetracyclines
    • 7.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7. Combination therapies
    • 7.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.8. Cephalosporins
    • 7.8.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.9. Others
    • 7.9.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. U.S. Antibiotic Resistance Market: Mechanism of Action Estimates & Trend Analysis

  • 8.1. Mechanism of Action Segment Dashboard
  • 8.2. U.S. Antibiotic Resistance Market: Mechanism of Action Movement Analysis
  • 8.3. U.S. Antibiotic Resistance Market Size & Trend Analysis, by Mechanism of Action, 2018 to 2030 (USD Million)
  • 8.4. Protein Synthesis Inhibitors
    • 8.4.1. Market estimates and forecasts 2018 to 2030 (USD million)
  • 8.5. Cell Wall Synthesis Inhibitors
    • 8.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6. RNA Synthesis Inhibitors
    • 8.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7. DNA Synthesis Inhibitors
    • 8.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.8. Others
    • 8.8.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 9. U.S. Antibiotic Resistance Market: Distribution Channel Estimates & Trend Analysis

  • 9.1. Distribution Channel Segment Dashboard
  • 9.2. U.S. Antibiotic Resistance Market: Distribution Movement Analysis
  • 9.3. U.S. Antibiotic Resistance Market Size & Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Million)
  • 9.4. Retail Pharmacies
    • 9.4.1. Market estimates and forecasts 2018 to 2030 (USD million)
  • 9.5. Hospital Pharmacies
    • 9.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.6. Online Pharmacies
    • 9.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 10. Competitive Landscape

  • 10.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 10.2. Company/Competition Categorization
  • 10.3. Vendor Landscape
    • 10.3.1. Key company heat map analysis, 2024
  • 10.4. Company Profiles
    • 10.4.1. Melinta Therapeutics
      • 10.4.1.1. Company overview
      • 10.4.1.2. Financial performance
      • 10.4.1.3. Product benchmarking
      • 10.4.1.4. Strategic initiatives
    • 10.4.2. Merck & Co., Inc.
      • 10.4.2.1. Company overview
      • 10.4.2.2. Financial performance
      • 10.4.2.3. Product benchmarking
      • 10.4.2.4. Strategic initiatives
    • 10.4.3. Melinta Therapeutics LLC
      • 10.4.3.1. Company overview
      • 10.4.3.2. Financial performance
      • 10.4.3.3. Product benchmarking
      • 10.4.3.4. Strategic initiatives
    • 10.4.4. Theravance Biopharma.
      • 10.4.4.1. Company overview
      • 10.4.4.2. Financial performance
      • 10.4.4.3. Product benchmarking
      • 10.4.4.4. Strategic initiatives
    • 10.4.5. Paratek Pharmaceuticals, Inc.
      • 10.4.5.1. Company overview
      • 10.4.5.2. Financial performance
      • 10.4.5.3. Product benchmarking
      • 10.4.5.4. Strategic initiatives
    • 10.4.6. Seres Therapeutics
      • 10.4.6.1. Company overview
      • 10.4.6.2. Financial performance
      • 10.4.6.3. Product benchmarking
      • 10.4.6.4. Strategic initiatives
    • 10.4.7. AbbVie Inc.
      • 10.4.7.1. Company overview
      • 10.4.7.2. Financial performance
      • 10.4.7.3. Product benchmarking
      • 10.4.7.4. Strategic initiatives